Department of Radiation Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,China
Abstract： Objective To retrospectively analyze and compare the clinical efficacy and safety between fractionated stereotactic radiotherapy (FSRT) combined with and without temozolomide in the treatment of large brain metastases. Methods Between 2009 and 2017,84 patients with large brain metastases (tumor size ≥ 6 cm3) were recruited and assigned into the CRT group (concurrent TMZ and FSRT,n=42) and RT group (FSRT alone, n=42).The radiation dose was 52.0 Gy in 13 fractions or 52.5 Gy in 15 fractions. Patients were reexamined by magnetic resonance imaging (MRI) during treatment. The radiation field would be shrunk if the gross target volume (GTV) was reduced. The clinical efficacy was evaluated at postoperative 2 to 3 months. The primary end-point event was local recurrence-free survival (LRFS) and the secondary end-point events included intracranial progression-free survival (IPFS), progression-free survival (PFS), overall survival (OS), brain metastasis-specific survival (BMSS) and adverse events. The survival rates were assessed with Kaplan-Meier method and log-rank test and monovariate analysis. Results The median GTV in the CRT and RT groups was 16.9 cm3 and 15.7 cm3.During the treatment,75% of the lesions in the CRT group were reduced compared with 34% in the RT group (P=0.000).The local control (LC) rate in the CRT and RT groups was 100% and 98%.The median follow-up time was 16.1 months (range,2.1-105.7 months).In the CRT group, the LRFS (P=0.040),IPFS (P=0.022),PFS (P=0.045),OS (P=0.013) and BMSS (P=0.006) were significantly better than those in the RT group, respectively. In the CRT group, the incidence of grade Ⅰ-Ⅱ gastrointestinal adverse events was 33%, significantly higher compared with 26% in the RT group (P=0.006).No grade IV-V adverse events occurred in both groups. Conclusion Combined application of temozolomide and FSRT can further enhance the LC and survival rates and do not increase the risk of severe adverse events in patients diagnosed with large brain metastases.
. Case-control study of fractionated stereotactic radiotherapy combined with temozolomide for large brain metastases[J]. Chinese Journal of Radiation Oncology, 2018, 27(4): 348-353.
[1] Gavrilovic IT,Posner JB.Brain metastases:epidemiology and pathophysiology[J].J Neurooncol,2005,75(1):5-14.DOI:10.1007/s11060-004-8093-6. [2] Pinkham MB,Whitfield GA,Brada M.New developments in intracranial stereotactic radiotherapy for metastases[J].Clin Oncol (R CollRadiol),2015,27(5):316-323.DOI:10.1016/j.clon.2015.01.007. [3] Blonigen BJ,Steinmetz RD,Levin L,et al. Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery[J].Int J Radiat Oncol Biol Phys,2010,77(4):996-1001.DOI:10.1016/j.ijrobp.2009.06.006. [4] Minniti G,Clarke E,Lanzetta G,et al. Stereotactic radiosurgery for brain metastases:analysis of outcome and risk of brain radionecrosis[J].Radiat Oncol,2011,6(1):48-57.DOI:10.1186/1748-717X-6-48. [5] Kim YJ,Cho KH,Kim JY,et al. Single-dose versus fractionated stereotactic radiotherapy for brain metastases[J].Int J Radiat Oncol Biol Phys,2011,81(2):483-489.DOI:10.1016/j/ijrobp.2010.05.033. [6] Lischalk JW,Oermann E,Collins SP,et al. Five-fraction stereotactic radiosurgery (SRS) for single inoperable high-risk non-small cell lung cancer (NSCLC) brain metastases[J].Radiat Oncol,2015,10(1):216-223.DOI:10.1186/s13014-015-0525-2. [7] Van RJ,Heimans JJ,Van BJ,et al. Survival of human glioma cells treated with various combination of temozolomide and X-rays[J].Int J Radiat Oncol Biol Phys,2000,47(3):779-784.DOI:10.1016/s0360-3016(99)00539-8. [8] Chang JE,Khuntia D,Robins HI,et al. Radiotherapy and radiosensitizers in the treatment of glioblastomamultiforme[J].Clin Adv Hematol Oncol,2007,5(11):907-915. [9] Van NK,Van BJ,Stalpers LJ,et al. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastomamultiforme cell lines[J].Int J Radiat Oncol Biol Phys,2007,69(4):1246-1253.DOI:10.1016/j.ijrobp.2007.07.2366. [10] Chua D,Krzakowski M,Chouaid C,et al. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer:a randomized,open-label phase Ⅱ study[J].Clin Lung Cancer,2010,11(3):176-181.DOI:10.3816/CLC.2010.n.022. [11] Sperduto PW,Wang M,Robins HI,et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases:Radiation Therapy Oncology Group 0320[J].Int J Radiat Oncol Biol Phys,2013,85(5):1312-1318.DOI:10.1016/j.ijrobp.2012.11.042. [12] Hassler MR,Pfeifer W,Knocke TH,et al. Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer:a multicentric Austrian phase Ⅱ study[J].Wien Klin Wochenschrift,2013,125(15):481-486.DOI:10.1007/s00508-013-0402-07. [13] Gamboa-Vignolle C,Ferrari-Carballo T,Arrieta O,et al. Whole-brain irradiation with concomitant daily fixed-dose temozolomide for brain metastases treatment:a randomised phase Ⅱ trial[J].Radiother Oncol,2012,102(2):187-191.DOI:10.1016/j.radonc.2011.12.004. [14] 马玉超,肖建平,毕楠,等.大分割放疗联合替莫唑胺治疗大体积脑转移瘤的前瞻性临床研究[J].中华放射肿瘤学杂志,2016,25(4):320-326.DOI:10.3760/cma.j.issn.1004-4221.2016.04.005. Ma YCXiao JP,Bi N,et al. A prospective clinical study of large-segment radiotherapy combined with tamoxifen in the treatment of large-volume brain metastases[J].Chin J Radiat Oncol,2016,25(4):320-326.DOI:10.3760/cma.j.issn.1004-4221.2016.04.005. [15] JiangXS,Xiao JP,Zhang Y,et al. Hypofractionated stereotactic radiotherapy for brain metastases larger than three centimeters[J].Radiat Oncol,2012,7:36-42.DOI:10.1186/1748-717X-7-36. [16] Weller M,Stupp R,Reifenberger G,et al. MGMT promoter methylation in malignant gliomas:ready for personalized medicine[J].Nat Rev Neurol,2010,6(1):39-51.DOI:10.1038/nrneurol.2009.197. [17] Ma W,Li N,An Y,et al. Effects of temozolomide and radiotherapy on brain metastatic tumor:a systematic review and meta-analysis[J].World Neurosurg,2016,92(1):197-205.DOI:10.1016/j.wneu.2016.04.011. [18] Chong JU,Ahn SG,Lee HM,et al. Local control of brain metastasis:treatment outcome of focal brain treatments in relation to subtypes[J].J Breast Cancer,2015,18(1):29-35.DOI:10.4048/jbc.2015.18.1.29. [19] Wang Y,Li P,Shen XF,et al. Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients[J].Eur J Med Res,2012,17(1):25.DOI:10.1186/2047-738X-17-25. [20] Emmanouil F,Martin H,Gunnar S,et al. Stereotactic radiosurgery and fractionated stereotactic radiotherapy:comparison of efficacy and toxicity in 260 patients with brain metastases[J].J Neurooncol,2012,109(1):91-98.DOI:10.1007/s11060-012-0868-6. [21] Wiggenraad R,Verbeek-de Kanter A,Mast M,et al. Local progression and pseudo progression after single fraction or fractionated stereotactic radiotherapy for large brain metastases[J].StrahlentherOnkol,2012,188(2):696-701.DOI:10.1007/s00066-012-0122-3. [22] Chinnaiyan P,Huang S,Vallabhaneni G,et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva)[J].Cancer Res,2005,65(8):3328-3335.DOI:10.1158/0008-5472.CAN-04-3547. [23] Jiang T,Min W,Li Y,et al. Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases:an update meta-analysis[J].Cancer Med,2016,5(6):1055-1065.DOI:10.1002/cam4.673.
2018, Vol. 27 
